The estimated Net Worth of Howard W Donnelly is at least $1.04 million dollars as of 20 April 2022. Mr. Donnelly owns over 6,022 units of Angiodynamic Inc stock worth over $777,126 and over the last 21 years he sold ANGO stock worth over $0. In addition, he makes $262,008 as Independent Chairman of the Board at Angiodynamic Inc.
Howard has made over 10 trades of the Angiodynamic Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 6,022 units of ANGO stock worth $96,051 on 20 April 2022.
The largest trade he's ever made was exercising 20,000 units of Angiodynamic Inc stock on 17 October 2013 worth over $220,000. On average, Howard trades about 2,668 units every 82 days since 2004. As of 20 April 2022 he still owns at least 104,734 units of Angiodynamic Inc stock.
You can see the complete history of Mr. Donnelly stock trades at the bottom of the page.
Howard W. Donnelly serves as Independent Chairman of the Board of the Company. Since 2017, Mr. Donnelly has been President and CEO of Bluefin Medical, a spin off of Concert Medical, LLC. BlueFin Medical is a company focused on the regional anesthesia market. From 2005 to March 2018, Mr. Donnelly was President of Concert Medical LLC, a manufacturer of interventional medical devices. Concert Medical was acquired by Theragenics in March 2018. From 2010 to 2016, Mr. Donnelly was President and CEO of HydroCision Inc., a company focused on spine surgery and the pain management market. Mr. Donnelly is currently the HydroCision's Chairman of the Board. From 2002 to 2008, Mr. Donnelly was a director and member of the audit, compensation and nominating and governance committees of Vital Signs, Inc. From 1999 to 2002, he was President of Level 1, Inc., a medical device manufacturer and subsidiary of Smiths Group. From 1990 to 1999, Mr. Donnelly was employed at Pfizer, Inc., with his last position as Vice President, Business Planning and Development for Pfizer’s Medical Technology Group from 1997 to 1999. Mr. Donnelly holds a B.S. and an M.B.A. from Bryant College.
As the Independent Chairman of the Board of Angiodynamic Inc, the total compensation of Howard Donnelly at Angiodynamic Inc is $262,008. There are 11 executives at Angiodynamic Inc getting paid more, with James Clemmer having the highest compensation of $3,116,630.
Howard Donnelly is 59, he's been the Independent Chairman of the Board of Angiodynamic Inc since 2014. There are 4 older and 22 younger executives at Angiodynamic Inc. The oldest executive at Angiodynamic Inc is Dennis Meteny, 67, who is the Independent Director.
Howard's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.
Over the last 21 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman et Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Angiodynamic Inc executives and other stock owners filed with the SEC include: